SMARCB1 and neoplasm: The determination of SMARCB1 inactivation with loss of protein expression, mainly assessed by immunohistochemical methods, is now the gold standard procedure applied to confirm diagnosis of suspected AT/RT cases and to differentiate those from morphologically similar tumours.